Dabur India Limited

INR 11,000

– Business Highlights ESG & Dividend Update FY23 - Performance Highlights Consol Revenue crosses INR 11,000 cr to close FY23 at Consol Revenue Growth in FY23 Consol Revenue 3-year CAGR INR 11,530 cr 5.9%

INR 11,530

rosses INR 11,000 cr to close FY23 at Consol Revenue Growth in FY23 Consol Revenue 3-year CAGR INR 11,530 cr 5.9% 10% India Business crosses 8,500 cr to close the FY23 at India Business Revenue Growth

5.9%

000 cr to close FY23 at Consol Revenue Growth in FY23 Consol Revenue 3-year CAGR INR 11,530 cr 5.9% 10% India Business crosses 8,500 cr to close the FY23 at India Business Revenue Growth in FY23

10%

to close FY23 at Consol Revenue Growth in FY23 Consol Revenue 3-year CAGR INR 11,530 cr 5.9% 10% India Business crosses 8,500 cr to close the FY23 at India Business Revenue Growth in FY23 Indi

INR 8,684

s 8,500 cr to close the FY23 at India Business Revenue Growth in FY23 India Revenue 3-year CAGR INR 8,684 cr 6.2% 11% Consol Operating Profit in FY23 Operating Profit Growth in FY23 Operating Profit M

6.2%

close the FY23 at India Business Revenue Growth in FY23 India Revenue 3-year CAGR INR 8,684 cr 6.2% 11% Consol Operating Profit in FY23 Operating Profit Growth in FY23 Operating Profit Margin in

11%

the FY23 at India Business Revenue Growth in FY23 India Revenue 3-year CAGR INR 8,684 cr 6.2% 11% Consol Operating Profit in FY23 Operating Profit Growth in FY23 Operating Profit Margin in FY2

INR 2,164

onsol Operating Profit in FY23 Operating Profit Growth in FY23 Operating Profit Margin in FY23 INR 2,164 cr (4.0%) 18.8% Reported PAT after Minority in FY23 Profit before exceptional items and amorti

4.0%

Profit in FY23 Operating Profit Growth in FY23 Operating Profit Margin in FY23 INR 2,164 cr (4.0%) 18.8% Reported PAT after Minority in FY23 Profit before exceptional items and amortization (P

18.8%

in FY23 Operating Profit Growth in FY23 Operating Profit Margin in FY23 INR 2,164 cr (4.0%) 18.8% Reported PAT after Minority in FY23 Profit before exceptional items and amortization (Pbeia)* i

INR 1,707

n FY23 Profit before exceptional items and amortization (Pbeia)* in FY23 Pbeia Growth in FY23 INR 1,707 cr INR 1,718 cr (5.8%) *Exceptional items and amortization: TY of INR 11 cr related to our share

INR 1,718

t before exceptional items and amortization (Pbeia)* in FY23 Pbeia Growth in FY23 INR 1,707 cr INR 1,718 cr (5.8%) *Exceptional items and amortization: TY of INR 11 cr related to our share of amortizatio

Exceptional Items

2

Amortization

2

Amortization

Amortization (impact on Net Profit after minority)* 11 0 Profit before exceptional items and amortization (Pbeia) 1,718 1,824 (5.8%) *Amortization flowing to Depreciation & Amortization in P&L: INR 21.87 cr FY23 – Domestic FMCG Growth – By Verticals Sales Contribution by Verticals FY22 FY23 Healthcare Home & Personal Care (HPC) Food & Beverage (F&B)* 3-year CAGR: 9% 3-year CAGR: 9% 3-year CAGR: 22% 2,645 2,772 2,581 2,006 2,964 3,245 3,657 3,846 1,724 1,326 946 891 32% 5% (7%) 9% 13% 5% (6%) 49% 30% FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 *F&B doesn’t include Badshah FY23 – International Business Performance FY22 Others 2.3% International 26.0% Sales Contribution FY23 Others 3.6% International 25.1% Domestic 71.7% Domestic 71.3% International Business grew by 11% in CC terms (2.2% in INR terms) FY23 Constant Currency Growth % 90.0% 28.4% (11.7%) 9.5% (3.7%) 10.7% MENA Egypt SSA Consol Namaste Turkey SAARC AGENDA 1 FY23 Performance Summary 2 3 4 Q4 FY23 – Performance

Amortization

Amortization (impact on Net Profit after minority)* 11 0 Profit before exceptional items and amortization (Pbeia) 312 379 (17.7%) *Amortization flowing to Depreciation & Amortization in P&L: INR 21.87 cr AGENDA 1 FY23 Performance Summary 2 3 4 Q4 FY23 – Performance Summary FY23 & Q4 FY23 – Business Highlights ESG & Dividend Update FY23 & Q4 FY23 | Business Highlights – Healthcare Health Supplements Digestives OTC & Ethicals FY23 Growth % (12.4%) 10.4% FY23 : 3-year CAGR 8.1% Q4 FY23 Growth % (3.3%) Q4 FY23 : 3-year CAGR 8.1% 8.3% 5.6% 8.6% (4.2%) 12.3% (0.4%) 13.6% • Health Supplements lapping • The portfolio saw strong growth • OTC business recorded flattish high bases of Covid years, during FY23 on a high base of performance in FY23 on account leading to 3-year FY CAGR of 8.1% 12.6% growth of high covid base- Honitus & Category Highlights • Market share gains continue in • FY Growth driven by Hajmola and Chyawanprash and Honey Pudin Hara franchises categories Shilajit portfolios post